Aspire Biopharma Holdings (ASBP) Income from Continuing Operations (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Income from Continuing Operations of 3222892.0 for Q1 2026, up 79.78% year-over-year from 1792658.81 in Q1 2025, and up 60.13% quarter-over-quarter from 8082817.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Income from Continuing Operations for 3 consecutive years, with 3222892.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 79.78% year-over-year to 3222892.0; the TTM figure through Mar 2026 stood at 29872592.0 (changed N/A YoY), while the FY2025 annual figure was 19339870.0, down 1376.47% from the prior year.
- Income from Continuing Operations advanced to 3222892.0 in Q1 2026 per ASBP's latest filing, from 8082817.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 216269.0 in Q3 2024 and bottomed at 15941328.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 5114083.33 across 3 years, with a median of 2924223.5 in 2025.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slumped 1257.0% — and 2026, when it surged 79.78%.
- Aspire Biopharma Holdings' Income from Continuing Operations stood at 595639.0 in 2024, then plunged by 1257.0% to 8082817.0 in 2025, then jumped by 60.13% to 3222892.0 in 2026.
- Business Quant data shows ASBP's Income from Continuing Operations at 3222892.0 in Q1 2026, 8082817.0 in Q4 2025, and 2625555.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.27 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -8.08 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -595,639.00 |
| Sep 30, 2024 | -216,269.00 |